Trillium Asset Management LLC Buys 140,012 Shares of Elanco Animal Health Incorporated $ELAN

Trillium Asset Management LLC bought a new stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN – Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 140,012 shares of the company’s stock, valued at approximately $3,135,000.

A number of other institutional investors also recently added to or reduced their stakes in the business. Sapient Capital LLC grew its stake in shares of Elanco Animal Health by 0.3% in the second quarter. Sapient Capital LLC now owns 128,573 shares of the company’s stock worth $3,164,000 after purchasing an additional 420 shares in the last quarter. Ritholtz Wealth Management increased its holdings in shares of Elanco Animal Health by 5.0% during the third quarter. Ritholtz Wealth Management now owns 9,335 shares of the company’s stock valued at $209,000 after purchasing an additional 446 shares during the period. Covestor Ltd increased its holdings in shares of Elanco Animal Health by 48.2% during the third quarter. Covestor Ltd now owns 1,383 shares of the company’s stock valued at $31,000 after purchasing an additional 450 shares during the period. Farther Finance Advisors LLC raised its stake in shares of Elanco Animal Health by 12.5% during the third quarter. Farther Finance Advisors LLC now owns 4,184 shares of the company’s stock valued at $94,000 after purchasing an additional 464 shares in the last quarter. Finally, North Dakota State Investment Board raised its stake in shares of Elanco Animal Health by 3.4% during the third quarter. North Dakota State Investment Board now owns 15,132 shares of the company’s stock valued at $339,000 after purchasing an additional 496 shares in the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

Insider Activity at Elanco Animal Health

In other news, insider Shiv O’Neill bought 3,998 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The stock was acquired at an average price of $23.58 per share, with a total value of $94,272.84. Following the completion of the purchase, the insider directly owned 87,832 shares of the company’s stock, valued at $2,071,078.56. This represents a 4.77% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Lawrence Kurzius bought 40,000 shares of the stock in a transaction that occurred on Thursday, August 20th. The shares were purchased at an average cost of $23.40 per share, for a total transaction of $936,000.00. Following the completion of the acquisition, the director owned 188,647 shares of the company’s stock, valued at $4,414,339.80. This trade represents a 26.91% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Company insiders own 1.14% of the company’s stock.

Elanco Animal Health Stock Performance

Shares of NYSE ELAN opened at $26.80 on Monday. The stock has a fifty day moving average price of $23.38 and a two-hundred day moving average price of $23.88. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.07 and a current ratio of 2.09. The firm has a market cap of $13.40 billion, a P/E ratio of -89.33, a PEG ratio of 2.26 and a beta of 1.73. Elanco Animal Health Incorporated has a 1 year low of $19.40 and a 1 year high of $27.98.

Elanco Animal Health (NYSE:ELAN – Get Free Report) last issued its quarterly earnings results on Friday, November 6th. The company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.20 by $0.07. Elanco Animal Health had a positive return on equity of 8.80% and a negative net margin of 2.86%. The company had revenue of $1.26 billion for the quarter, compared to analysts’ expectations of $1.21 billion. During the same period last year, the firm earned $0.19 EPS. The firm’s revenue for the quarter was up 11.3% on a year-over-year basis. Elanco Animal Health has set its Q4 2026 guidance at 0.160-0.190 EPS and its FY 2026 guidance at 1.170-1.200 EPS. Research analysts forecast that Elanco Animal Health Incorporated will post 1.18 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ELAN has been the subject of several research analyst reports. Morgan Stanley reduced their price objective on shares of Elanco Animal Health from $26.00 to $25.00 and set an “equal weight” rating for the company in a report on Thursday, October 29th. Jefferies Financial Group lowered shares of Elanco Animal Health from a “buy” rating to a “hold” rating and decreased their target price for the company from $31.00 to $24.00 in a research report on Tuesday, October 20th. UBS Group raised their target price on shares of Elanco Animal Health from $31.00 to $33.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Weiss Ratings upgraded shares of Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday, September 4th. Finally, KeyCorp restated an “overweight” rating on shares of Elanco Animal Health in a research report on Monday, November 9th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Elanco Animal Health presently has an average rating of “Moderate Buy” and an average target price of $29.75.

Check Out Our Latest Report on Elanco Animal Health

Elanco Animal Health Company Profile

(Free Report)

Elanco Animal Health is a global animal health company that develops, manufactures and markets products for companion animals and livestock. Its offerings include medicines, vaccines and other products intended to prevent and treat disease and support animal health. For pets, Elanco provides treatments for conditions including parasitic infections, pain and chronic diseases. Its livestock products support the health of animals such as cattle, poultry, swine and fish, serving producers and veterinarians.

See Also

Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELAN – Free Report).

Institutional Ownership by Quarter for Elanco Animal Health (NYSE:ELAN)

Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.